Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Panobinostat Lactate

October 2024

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Panobinostat lactate

Dosage Form: Capsule

Route: Oral

Strengths: EQ 10 mg Base, EQ 15 mg Base, EQ 20 mg Base

Recommended Study: One in vivo bioequivalence study with pharmacokinetic endpoints

Study design: Single-dose, two-treatment, two-period crossover in vivo
Strength: EQ 20 mg Base
Subjects: Patients with multiple myeloma on a well-established dosing regimen of panobinostat (once every other day for 3 doses per week (Mondays, Wednesdays, and Fridays) in Weeks 1 and 2 of each 21-day cycle) as well as bortezomib and dexamethasone
Additional comments: For the purpose of a bioequivalence study, patients should be administered with the drug product under similar food conditions during both periods. To avoid pre-dose plasma concentrations, full pharmacokinetic profiles of bioequivalence study for the test product and reference listed drug (RLD) are recommended from all patients dosed on Day 1 (Monday) of each therapeutic cycle. The pharmacokinetics of panobinostat should be characterized during the sampling period of 48 hrs. Submission of an investigational new drug application is required prior to the conduct of a bioequivalence study for a cytotoxic drug of panobinostat pursuant to 21 CFR § 320.31.

Analyte to measure: Panobinostat in plasma

Bioequivalence based on (90% CI): Panobinostat

Waiver request of in vivo testing: EQ 10 mg Base and EQ 15 mg Base strengths based on (i) an acceptable bioequivalence study on the EQ 20 mg Base strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA's Dissolution Methods database, http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units for each of all strengths of the test product and RLD.[1] Specifications will be determined upon review of the abbreviated new drug application.

Document History: Recommended December 2016; Revised October 2024

Unique Agency Identifier: PSG_205353

[1] If the RLD is not available, refer to the most recent version of the FDA guidance for industry on *Referencing Approved Drug Products in ANDA Submissions*.